Dr. Ruan on Stratifying Risk in MCL | OncLive

Dr. Ruan on Stratifying Risk in MCL

June 8, 2020

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses stratifying risk in mantle cell lymphoma (MCL).

MCL is a rare subtype of non-Hodgkin lymphoma that accounts for approximately 5% to 8% of all patients with B-cell non-Hodgkin lymphoma, says Ruan.

Moreover, MCL is associated with unique clinical and pathological features, including translocation 11;14 and cyclin D1 expression, explains Ruan.

Through the use of stratification tools that examine these features, such as the Mantle Cell Lymphoma International Prognostic Index, the risk associated with a patient’s disease can be determined, concludes Ruan.


x